SCHEMBL2624129

SCHEMBL2624129

CCOC(=O)c1cc2c(c(O)n1)CCCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 6/20 0.52
KDM4E B2RXH2 6/20 0.48
CYP1A2 P05177 2/20 0.44
ALDH1A1 P00352 5/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
PPARG P37231 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
ACHE P22303 3/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CASP3 P42574 1/20 0.41
ATM Q13315 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16506329 0.83 NLRP3 (0.55) NLRP3KDM4ECYP1A2ALDH1A1KMT2A
SCHEMBL29852430 0.78 NLRP3 (0.47) NLRP3KDM4ECYP1A2ALDH1A1KMT2A
SCHEMBL12072482 0.77 ACHE (0.50) NLRP3KDM4ECYP1A2ALDH1A1SMN1; SMN2
SCHEMBL2624121 0.75 LMNA (0.40) KDM4EALDH1A1KMT2ASMN1; SMN2LMNA
SCHEMBL3329593 0.75 GABRA1 (0.56) NLRP3KDM4ECYP1A2ALDH1A1KMT2A
SCHEMBL2865009 0.74 CA12 (0.51) NLRP3KDM4EKMT2ASMN1; SMN2NPC1
SCHEMBL9987432 0.73 ACHE (0.49) NLRP3KDM4ECYP1A2ALDH1A1SMN1; SMN2
SCHEMBL3553700 0.73 CA12 (0.50) NLRP3KDM4ECYP1A2ALDH1A1KMT2A
SCHEMBL3328393 0.72 GABRA1 (0.56) NLRP3KDM4ECYP1A2ALDH1A1SMN1; SMN2
SCHEMBL16750520 0.71 KDM4E (0.51) NLRP3KDM4ECYP1A2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 US disclosed
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 US disclosed
WO-2012054874-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, EIF4A2 NLRP3 3607/4885KDM4E 507/4885CYP1A2 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.